AFKLMP Cargo expands pharma capabilities at Schiphol
23 / 09 / 2020
In preparation for the widespread distribution of Covid-19 vaccines when they become available, Air France KLM Martinair Cargo (AFKLMP Cargo) is building a new temperature-controlled room at its Schiphol Pharma Hub.
The room will be able to store pharma between temperatures of 2°C and 8°C.
Other features of the room include: additional 2,061 cu m of storage space; a dangerous goods and dry ice compatible service; 152 additional skid positions; a flexible racks to accommodate odd-sized shipments; monitoring from a central control room;a temperature alarm system; a speed door to limit external exposure; and a synthetic floor.
Enrica Calonghi (pictured), global head of pharmaceutical logistics at AFKLMP Cargo, commented: “Just a few months ago, AFKLMP Cargo already invested in 1,118 cu m of additional controlled-climate room (CRT) at Schiphol using the same hybrid technology. With the construction of this new climate-cool room, we will be as flexible as possible to handle more vaccines if necessary.”
GertJan Roelands, senior vice president of sales and distribution at AFKLMP Cargo, added: “The transportation of pharmaceuticals and other healthcare goods is a strategic priority for AFKLMP Cargo. We are thrilled with this investment, which will further improve the service standards of our Schiphol Pharma Hub. We will keep improving infrastructure, introducing digital initiatives and pursuing others innovations to meet the highest industry standards for transporting pharmaceuticals and other healthcare goods. This is essential when it comes to shipping Covid-19 vaccines.”
In addition, AFKLMP Cargo is improving its services and investing in infrastructure at its Paris Charles de Gaulle and Amsterdam Schiphol hubs.
A spokesperson for the company said: “We know how important it is to guarantee the required quality, reliability and connectivity throughout supply chains. Our customers can therefore book their valuable pharma via our myCargo portal, where we offer clarity on capacity, infrastructure and capabilities at our CDG and AMS hubs, but also at more than 120 pharma destinations worldwide.”
